National Rosacea Society

Last updated

National Rosacea Society
AbbreviationNRS
Founded1992;32 years ago (1992)
Legal status 501(c)(3) non-profit organization
Headquarters Chicago, Illinois
Area served
United States
Website www.rosacea.org

The National Rosacea Society (NRS) is a 501(c) nonprofit organization dedicated to improving the lives of the estimated 16 million Americans who suffer from rosacea, a chronic facial skin disorder. Its mission is to raise awareness, provide health information, and support medical research that may lead to improvement in the management, prevention, and potential cure for rosacea. [1]

Contents

History

Although rosacea was first described by Guy de Chauliac in the 14th century and included Chaucer's The Canterbury Tales , [2] when the National Rosacea Society was founded in 1992 rosacea was still considered a rare disease, and its first approved treatment, topical metronidazole, received orphan drug designation by the U.S. Food and Drug Administration in the belief that fewer than 200,000 Americans suffered from it. [3] It soon became evident that rosacea affected the lives of millions, who had previously failed to realize they had a medical condition that could be treated. A 2018 study estimated global incidence of rosacea to be more than 5%, or equivalent to around 415 million. [4]

Awareness

The National Rosacea Society designates each April as Rosacea Awareness Month [5] and conducts national communications, public relations, and social media activities throughout the year. The society also produces patient education materials. [6]

In 2024, the Society launched a Seal of Acceptance program to identify gentle skin care and cosmetic products that have been clinically tested and evaluated to be unlikely to irritate rosacea skin. [7] [8]

Support for research

In 1999, [9] the National Rosacea Society launched a patient-funded research grants program to support scientific research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. Because the etiology of rosacea is unknown, a high priority in awarding grants is given to studies relating to such areas as the pathogenesis, progression, mechanism of action, cell biology, and potential genetic factors of rosacea. Research in such areas as epidemiology, predisposition, quality of life, and relationships with environmental and lifestyle factors may also be funded. [10]

Since its inception, more than $1.5 million has been awarded to support more than 70 studies. [11]

Publications

To provide a basis for meaningful scientific investigation, the NRS organized a consensus committee and review panel of 21 medical experts to establish a standard definition and classification system for rosacea, published in 2002, [12] as well as a standard grading system published in 2004. [13] The classification system was instrumental in establishing the clinical subtypes—erythematotelangiectatic rosacea, papulopustular rosacea, phymatous rosacea, and ocular rosacea—commonly used to describe the disease. [14] [15] In 2009, an NRS consensus committee and review panel of 26 medical experts published standard management options for rosacea. [16] [17]

In 2017, an NRS consensus committee and review panel of 28 medical experts published an updated classification and pathophysiology of rosacea, [18] reflecting the increased understanding of the disease and its progression gained in the 15 years since the original classification was published. The updated classification shifted focus away from subtypes to a phenotype approach to diagnosis. [19] [20] The article was accompanied by an editorial on rosacea comorbidities and areas for future research. [21]

In 2020, an NRS consensus committee and review panel of 27 medical experts published updates standard management options for rosacea, [22] intended to provide a comprehensive summary of treatment options for the respective phenotypes identified in the updated standard classification of rosacea, and recommending that physicians to tailor therapy to each patient's individual case. [23]

Related Research Articles

<span class="mw-page-title-main">Acne</span> Skin condition characterized by pimples

Acne, also known as acne vulgaris, is a long-term skin condition that occurs when dead skin cells and oil from the skin clog hair follicles. Typical features of the condition include blackheads or whiteheads, pimples, oily skin, and possible scarring. It primarily affects skin with a relatively high number of oil glands, including the face, upper part of the chest, and back. The resulting appearance can lead to lack of confidence, anxiety, reduced self-esteem, and, in extreme cases, depression or thoughts of suicide.

<span class="mw-page-title-main">Psoriasis</span> Skin disease

Psoriasis is a long-lasting, noncontagious autoimmune disease characterized by patches of abnormal skin. These areas are red, pink, or purple, dry, itchy, and scaly. Psoriasis varies in severity from small localized patches to complete body coverage. Injury to the skin can trigger psoriatic skin changes at that spot, which is known as the Koebner phenomenon.

<span class="mw-page-title-main">Alopecia areata</span> Medical condition

Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all areas of the body. It often results in a few bald spots on the scalp, each about the size of a coin. Psychological stress and illness are possible factors in bringing on alopecia areata in individuals at risk, but in most cases there is no obvious trigger. People are generally otherwise healthy. In a few cases, all the hair on the scalp is lost, or all body hair is lost. Hair loss can be permanent, or temporary.

<span class="mw-page-title-main">Minocycline</span> Antibiotic medication

Minocycline, sold under the brand name Minocin among others, is a tetracycline antibiotic medication used to treat a number of bacterial infections such as some occurring in certain forms of pneumonia. It is generally less preferred than the tetracycline doxycycline. Minocycline is also used for the treatment of acne and rheumatoid arthritis. It is taken by mouth or applied to the skin.

<span class="mw-page-title-main">Dihydroxyacetone</span> Chemical compound

Dihydroxyacetone, also known as glycerone, is a simple saccharide with formula C
3
H
6
O
3
.

<span class="mw-page-title-main">Hidradenitis suppurativa</span> Human disease

Hidradenitis suppurativa (HS), sometimes known as acne inversa or Verneuil's disease, is a long-term dermatological condition characterized by the occurrence of inflamed and swollen lumps. These are typically painful and break open, releasing fluid or pus. The areas most commonly affected are the underarms, under the breasts, perineum, buttocks, and the groin. Scar tissue remains after healing. HS may significantly limit many everyday activities, for instance, walking, hugging, moving, and sitting down. Sitting disability may occur in patients with lesions in sacral, gluteal, perineal, femoral, groin or genital regions; and prolonged periods of sitting down can also worsen the condition of the skin of these patients.

<span class="mw-page-title-main">Doxycycline</span> Tetracycline-class antibiotic

Doxycycline is a broad-spectrum antibiotic of the tetracycline class used in the treatment of infections caused by bacteria and certain parasites. It is used to treat bacterial pneumonia, acne, chlamydia infections, Lyme disease, cholera, typhus, and syphilis. It is also used to prevent malaria. Doxycycline may be taken by mouth or by injection into a vein.

<span class="mw-page-title-main">Rosacea</span> Skin condition resulting in redness, pimples and swelling, usually on the face

Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples, swelling, and small and superficial dilated blood vessels. Often, the nose, cheeks, forehead, and chin are most involved. A red, enlarged nose may occur in severe disease, a condition known as rhinophyma.

Ocular rosacea is a type of rosacea that affects the eyes. Signs and symptoms generally consist of redness, irritation or burning of the eyes. Affected individuals may also feel that there is something, such as an eyelash, in the eye and frequently have redness of the nose and cheeks as well. Complications include corneal ulcer.

<span class="mw-page-title-main">Azelaic acid</span> Organic chemical compound

Azelaic acid (AzA) is an organic compound with the formula HOOC(CH2)7COOH. This saturated dicarboxylic acid exists as a white powder. It is found in wheat, rye, and barley. It is a precursor to diverse industrial products including polymers and plasticizers, as well as being a component of a number of hair and skin conditioners. AzA inhibits tyrosinase.

Acne fulminans is a severe form of the skin disease, acne, which can occur after unsuccessful treatment for another form of acne, acne conglobata. The condition is thought to be an immunologically induced disease in which elevated level of testosterone causes a rise in sebum and population of Cutibacterium acnes bacteria. The increase in the amount of C acnes or related antigens may trigger the immunologic reaction in some individuals and lead to an occurrence of acne fulminans. In addition to testosterone, isotretinoin may also precipitate acne fulminans, possibly related to highly increased levels of C acnes antigens in the patient's immune system. Acne fulminans is a rare disease. Over the past several years, fewer cases of this disease have occurred, possibly because of earlier and better treatment of acne. Approximately 100 patients with acne fulminans have been described.

Antonella Tosti is an Italian physician and scientist with major contributions in the field of dermatology, including developing dermoscopy for the diagnosis and care of hair diseases, a world recognized expert in hair disorders. Her contributions to knowledge about nails include research about videodermoscopy of the hyponychium and the nail plate.

<span class="mw-page-title-main">Pimple</span> Type of comedo

A pimple or zit is a kind of comedo that results from excess sebum and dead skin cells getting trapped in the pores of the skin. In its aggravated state, it may evolve into a pustule or papule. Pimples can be treated by acne medications, antibiotics, and anti-inflammatories prescribed by a physician, or various over the counter remedies purchased at a pharmacy.

Richard L. Gallo is an American dermatologist who is a Distinguished Professor and founding Chairman of Dermatology at the University of California, San Diego. His research accomplishments as a physician-scientist include discovery of antimicrobial peptides in mammalian skin, establishing new links between innate immunity and skin diseases such as atopic dermatitis and rosacea, and defining the functions of the skin microbiome in host immune defense.

Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.

Primary cutaneous follicle center lymphoma is a type of lymphoma. It was recognized as a distinct disease entity in the 2008 WHO classification. PCFCL had been previously conceived as a variant of follicular lymphoma (FL).

<span class="mw-page-title-main">Topical steroid withdrawal</span> Medical condition

Topical steroid withdrawal, also known as red burning skin and steroid dermatitis, has been reported in people who apply topical steroids for 2 weeks or longer and then discontinue use. Symptoms affect the skin and include redness, a burning sensation, and itchiness, which may then be followed by peeling.

International Dermoscopy Society (IDS) is a non-governmental organization offering comprehensive promotion of dermoscopy, also known as dermatoscopy. It has over 16,000 international members from over 160 different countries.

Maskne is a portmanteau of "mask" and "acne". The term appeared in use during the COVID-19 pandemic in 2020 to refer to acne and other rashes of the face that occur in association with mask wearing. The findings are observational only and related to pressure, occlusion and friction. It is likely that several are perioral dermatitis, rosacea, seborrheic dermatitis, folliculitis, irritant contact dermatitis or allergic contact dermatitis, and acne mechanica. In one article, maskne is observed to be caused by increase of humidity in the occluded area and sebum being secreted, increasing the amount of squalene on the skin. This, along with excess sweating lead to the swelling of epidermal keratinocytes, causing acute obstruction and acne aggravation. The hot and humid environment in which maskne is induced is also apparent with tropical acne. The best treatment for maskne is to avoid wearing a mask.

<span class="mw-page-title-main">Light-emitting diode therapy</span>

Light-emitting diode therapy (LEDT) is a clinical approach that applies different wavelengths of light to cure diseases or conditions with skin-safe lights. Following NASA's innovation in the 1990s with Light Emitting Diodes (LEDs) that emit a specific narrow light spectrum, LED Therapy (LEDT) showed significant potential. The high precision of narrow-band LED therapy enabled its first use in clinical practices. The commonly used lights in LEDT are blue, red, green, yellow, and infrared (IR).

References

  1. "Guidestar: National Rosacea Society" . Retrieved May 2, 2019.
  2. Rolleston, JD (1933). "A Note on the Early History of Rosacea". Journal of the Royal Society of Medicine. 26 (4): 327–329. doi:10.1177/003591573302600401. PMC   2204565 . PMID   19989108.
  3. "Curatek's Topical Metrogel (Metronidazole) Gets Orphan Designation". The Pink Sheet. March 14, 1988. Retrieved April 26, 2019.
  4. Gether, L; Overgaard, LK; Egeberg, A; Thyssen, JP (2018). "Incidence and prevalence of rosacea: a systematic review and meta-analysis". British Journal of Dermatology. 179 (2): 282–289. doi: 10.1111/bjd.16481 . PMID   29478264.
  5. "National Rosacea Society designates April as "Rosacea Awareness Month"". Practical Dermatology. April 3, 2018. Retrieved May 2, 2019.
  6. "Q&A: Informed patients, physicians improve rosacea care". Healio Dermatology. April 2, 2021. Retrieved June 9, 2021.
  7. "National Rosacea Society Seal of Acceptance". rosacea.org. Retrieved March 5, 2024.
  8. Andrus, Emma; Draelos, Zoe Diana (February 13, 2024). "National Rosacea Society Launches Seal of Acceptance Program". Dermatology Times. Retrieved March 5, 2024.
  9. "Grants Program Is Set To Support Rosacea Research". Rosacea Review newsletter. Spring 1999. Retrieved April 26, 2019.
  10. "Research grants from outside organizations". American Academy of Dermatology. Retrieved May 2, 2019.
  11. "National Rosacea Society: New Grants Available in 2019". Practical Dermatology. December 19, 2018. Retrieved April 26, 2019.
  12. Wilkin, J; Dahl, M; Detmar, M; Drake, L; Feinstein, A; Odom, R; Powell, F (2002). "Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea". Journal of the American Academy of Dermatology. 46 (4): 584–587. doi:10.1067/mjd.2002.120625. PMID   11907512.
  13. Wilkin, J; Dahl, M; Detmar, M; Drake, L; Liang, MH; Odom, R; Powell, F (2004). "Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea". Journal of the American Academy of Dermatology. 50 (6): 907–912. doi:10.1016/j.jaad.2004.01.048. PMID   15153893.
  14. Reszko, AE; Granstein, RD (2008). "Pathogenesis of rosacea". Cosmetic Dermatology. 21 (4): 224–232. doi:10.1016/j.jaad.2004.01.048. PMID   15153893.
  15. Bolognia, Jean L; Lorizzo, Joseph L; Rapini, Ronald P (2003). Dermatology (1st ed.). Mosby. p. 546. ISBN   0323024092.
  16. Odom, R; Dahl, M; Dover, J; Draelos, Z; Drake, L; Macsai, M; Powell, F; Thiboutot, D; Webster, GF; Wilkin, J (2009). "Standard management options for rosacea, part 1: overview and broad spectrum of care". Cutis. 84 (1): 43–47. PMID   19743724.
  17. Odom, R.; Dahl, M.; Dover, J.; Draelos, Z.; Drake, L.; MacSai, M.; Powell, F.; Thiboutot, D.; Webster, G. F.; Wilkin, J.; National Rosacea Society Expert Committee on the Classification Staging of Rosacea (2009). "Standard management options for rosacea, part 2: Options according to subtype". Cutis. 84 (2): 97–104. PMID   19746768.
  18. Gallo, RL; Granstein, RD; Kang, S; Mannis, M; Steinhoff, M; Tan, J; Thiboutot, D (2018). "Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee". Journal of the American Academy of Dermatology. 78 (1): 148–155. doi:10.1016/j.jaad.2004.01.048. PMID   29089180.
  19. Tan, J; Berg, M; Gallo, RL; Del Rosso, JQ (2018). "Applying the phenotype approach for rosacea to practice and research". British Journal of Dermatology. 179 (3): 741–746. doi: 10.1111/bjd.16815 . PMID   29799114.
  20. "New Rosacea Classification System Encourages More Precise Assessment and Treatment". Practical Dermatology. July 11, 2018. Retrieved May 2, 2019.
  21. Gallo, RL; Granstein, RD; Kang, S; Mannis, M; Steinhoff, M; Tan, J; Thiboutot, D (2018). "Rosacea comorbidities and future research: The 2017 update by the National Rosacea Society Expert Committee". Journal of the American Academy of Dermatology. 78 (1): 167–170. doi:10.1016/j.jaad.2017.06.150. PMID   29102687. S2CID   19568272.
  22. Thiboutot, D; Anderson, R; Cook-Bolden, F; Draelos, Z; Gallo, RL; Granstein, RD; Kang, S; Gold, LS; Tan, J (2020). "Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee". Journal of the American Academy of Dermatology. 82 (6): 1501–1510. doi:10.1016/j.jaad.2020.01.077. PMID   32035944. S2CID   211071084.
  23. "New rosacea clinical management guidelines focus on symptomatology". Dermatology News. May 26, 2020. Retrieved July 28, 2020.